{"id":"topical-ocular-hypotensive-eye-drops","safety":{"commonSideEffects":[{"rate":"null","effect":"Blepharitis"},{"rate":"null","effect":"Dry eye"},{"rate":"null","effect":"Headache"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"Topical ocular hypotensive eye drops work by decreasing the production of aqueous humor in the eye, thereby reducing intraocular pressure. This is typically achieved through the inhibition of carbonic anhydrase or the reduction of prostaglandin synthesis.","oneSentence":"Reduces intraocular pressure by decreasing aqueous humor production.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:54:21.044Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Glaucoma"},{"name":"Ocular hypertension"}]},"trialDetails":[{"nctId":"NCT06190028","phase":"NA","title":"Evaluation of Performance and Safety of Carbopol 980 NF 0.2%- Based Medical Device in the Management of Patients With Glaucomar or Ocular Hypertension and Concomitant Dry Eye Syndrome on Multiple Long-term Topical Hypotensive Therapy","status":"TERMINATED","sponsor":"Fidia Farmaceutici s.p.a.","startDate":"2023-06-14","conditions":"Dry Eye Syndrome, Glaucoma and Concomitant Dry Eye Syndrome, Ocular Hypertension and Concomitant Dry Eye Syndrome","enrollment":65},{"nctId":"NCT06407973","phase":"PHASE4","title":"A Clinical Trial Comparing the OMNI Surgical System to Standard Medical Treatment in Patients With Primary Open Angle Glaucoma","status":"TERMINATED","sponsor":"Sight Sciences, Inc.","startDate":"2024-08-21","conditions":"Primary Open Angle Glaucoma","enrollment":2},{"nctId":"NCT04448080","phase":"NA","title":"Comparison of Topical Anesthesia and Analgosedation in Micropulse Transscleral Glaucoma Treatment","status":"COMPLETED","sponsor":"University of Zurich","startDate":"2020-06-01","conditions":"Glaucoma","enrollment":8},{"nctId":"NCT02873806","phase":"PHASE4","title":"Two Trabecular Micro-bypass Stents & Postoperative Travoprost to Treat Glaucoma Subjects on Two Hypotensive Agents","status":"COMPLETED","sponsor":"Glaukos Corporation","startDate":"2013-03","conditions":"Open-angle Glaucoma","enrollment":53},{"nctId":"NCT05474716","phase":"PHASE4","title":"The Effect of Topical Brimonidine on the Ocular Hemodynamics in Patients of POAG Using OCTA","status":"COMPLETED","sponsor":"Fayoum University","startDate":"2020-05-01","conditions":"Glaucoma, Primary Open Angle, Ocular Blood Flow, Optical Coherence Tomography Angiography","enrollment":41},{"nctId":"NCT05241938","phase":"NA","title":"PSLT Compared to Prostaglandin Analogue Eye Drops","status":"UNKNOWN","sponsor":"Federal University of Rio Grande do Sul","startDate":"2021-09-01","conditions":"Open Angle Glaucoma, Ocular Hypertension","enrollment":75},{"nctId":"NCT03284853","phase":"PHASE3","title":"Safety and Efficacy Study of PG324 (Netarsudil/Latanoprost 0.02% / 0.005%) Ophthalmic Solution Compared to GANFORT® Ophthalmic Solution in Open Angle Glaucoma or Ocular Hypertension","status":"COMPLETED","sponsor":"Aerie Pharmaceuticals","startDate":"2017-09-05","conditions":"Open Angle Glaucoma, Ocular Hypertension","enrollment":436},{"nctId":"NCT03844945","phase":"PHASE2","title":"Efficacy and Systemic Safety of Netarsudil 0.01%, 0.02%, 0.04% Relative to Placebo in Subjects With Open-angle Glaucoma or Ocular Hypertension in Japan","status":"COMPLETED","sponsor":"Aerie Pharmaceuticals","startDate":"2019-03-19","conditions":"Open Angle Glaucoma, Ocular Hypertension","enrollment":215},{"nctId":"NCT00000125","phase":"PHASE3","title":"Ocular Hypertension Treatment Study (OHTS)","status":"COMPLETED","sponsor":"Washington University School of Medicine","startDate":"1994-02","conditions":"Ocular Hypertension, Glaucoma","enrollment":1636},{"nctId":"NCT03365778","phase":"NA","title":"Educational Intervention to Adopt SLT as First-Line Glaucoma Treatment","status":"COMPLETED","sponsor":"Wills Eye","startDate":"2017-10-23","conditions":"Primary Open-angle Glaucoma","enrollment":86},{"nctId":"NCT03310580","phase":"PHASE2","title":"Study of Netarsudil Ophthalmic Solution in Japanese/Japanese-American Subjects With Open-angle Glaucoma or Ocular Hypertension","status":"COMPLETED","sponsor":"Aerie Pharmaceuticals","startDate":"2017-11-15","conditions":"Primary Open Angle Glaucoma or Ocular Hypertension","enrollment":42},{"nctId":"NCT03534882","phase":"NA","title":"Effects of Prostaglandin Analogue Washout Following Long-term Therapy in Adults With Primary Open Angle Glaucoma","status":"COMPLETED","sponsor":"Cindy Hutnik","startDate":"2014-05-27","conditions":"Primary Open-Angle Glaucoma, Mild Stage, Glaucoma, Suspect, Ocular Hypertension","enrollment":87},{"nctId":"NCT03480295","phase":"NA","title":"Effects of a PF Ophthalmic Solution Containing HA0.4% and TAU 0.5%","status":"COMPLETED","sponsor":"Fondazione G.B. Bietti, IRCCS","startDate":"2016-12-19","conditions":"Glaucoma","enrollment":39},{"nctId":"NCT01746602","phase":"PHASE3","title":"Effect of Topical Glaucoma Therapy on Tear Film Stability in Healthy Subjects","status":"TERMINATED","sponsor":"Medical University of Vienna","startDate":"2011-07","conditions":"Healthy","enrollment":38},{"nctId":"NCT02522039","phase":"NA","title":"Pupillary Response After Glaucoma Medication","status":"COMPLETED","sponsor":"Glostrup University Hospital, Copenhagen","startDate":"2014-05","conditions":"Drug Effect (Glaucoma Drugs)","enrollment":21},{"nctId":"NCT00800540","phase":"PHASE4","title":"Circadian Ocular Perfusion Pressure and Ocular Blood Flow","status":"COMPLETED","sponsor":"Alcon Research","startDate":"2009-02","conditions":"Glaucoma","enrollment":35}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Topical ocular hypotensive eye drops.","genericName":"Topical ocular hypotensive eye drops.","companyName":"Washington University School of Medicine","companyId":"washington-university-school-of-medicine","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Reduces intraocular pressure by decreasing aqueous humor production. Used for Glaucoma, Ocular hypertension.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}